Lipoatrophy
|
WikiDoc Resources for Lipoatrophy |
|
Articles |
|---|
|
Most recent articles on Lipoatrophy Most cited articles on Lipoatrophy |
|
Media |
|
Powerpoint slides on Lipoatrophy |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lipoatrophy at Clinical Trials.gov Clinical Trials on Lipoatrophy at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lipoatrophy
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Lipoatrophy Discussion groups on Lipoatrophy Patient Handouts on Lipoatrophy Directions to Hospitals Treating Lipoatrophy Risk calculators and risk factors for Lipoatrophy
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lipoatrophy |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutanous injections of insulin in the treatment of diabetes, or from subcutanous injections of Copaxone used for the treatment of multiple sclerosis. In the latter case, an injection may produce a small dent at the injection site.[1] Lipoatrophy is also an adverse drug reaction that is associated with some antiretroviral drugs.[2]
References
- ↑ Radermecker RP, Piérard GE, Scheen AJ (2007). "Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs". American journal of clinical dermatology. 8 (1): 21–8. PMID 17298103.
- ↑ Barbaro G (2007). "Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome". Curr. Pharm. Des. 13 (21): 2208–13. PMID 17627554.